The Origin of B-Cell Chronic Lymphocytic Leukemia

Paolo Ghia, Federico Caligaris-Cappio

Research output: Contribution to journalArticle

Abstract

An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen during the natural history of the disease. Unmutated (UM) cases show a remarkable skewing in IGHV gene usage. In addition, all CLL cases, both mutated (M) and UM, show a common surface phenotype which is significantly activated and similar to the surface phenotype of antigen (Ag)-experienced B cells. The properties of CLL B-cell receptors (BCR) resemble those observed in normal B cells upon Ag interaction, and gene profiling analyses revealed that both subsets share striking similarities with the so-called memory B cells. The detailed analyses of the complementary determining region 3 (CDR3) sequences of the leukemic immunoglobulin (Ig) receptors showed that unrelated patients in different parts of the world express very similar if not identical BCR. Remarkably, similar VHDJH rearrangements have been identified in both UM- and M-CLL, suggesting an antigenic selection in both subsets of the disease. From all this evidence, the concept has arisen that the cell of origin, regardless its mutational status, has to be "an Ag-experienced" B cell that gives rise to a malignant clone that appears to be more dynamic than previously appreciated and whose progression is favored by a number of molecular and cellular interactions that occur in tissues.

Original languageEnglish
Pages (from-to)150-156
Number of pages7
JournalSeminars in Oncology
Volume33
Issue number2
DOIs
Publication statusPublished - Apr 2006

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Antigens
Genes
Phenotype
Surface Antigens
Immunoglobulins
Clone Cells
Mutation

ASJC Scopus subject areas

  • Oncology

Cite this

The Origin of B-Cell Chronic Lymphocytic Leukemia. / Ghia, Paolo; Caligaris-Cappio, Federico.

In: Seminars in Oncology, Vol. 33, No. 2, 04.2006, p. 150-156.

Research output: Contribution to journalArticle

Ghia, Paolo ; Caligaris-Cappio, Federico. / The Origin of B-Cell Chronic Lymphocytic Leukemia. In: Seminars in Oncology. 2006 ; Vol. 33, No. 2. pp. 150-156.
@article{b7a86e0075d641ca8f09b41ff37bc091,
title = "The Origin of B-Cell Chronic Lymphocytic Leukemia",
abstract = "An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen during the natural history of the disease. Unmutated (UM) cases show a remarkable skewing in IGHV gene usage. In addition, all CLL cases, both mutated (M) and UM, show a common surface phenotype which is significantly activated and similar to the surface phenotype of antigen (Ag)-experienced B cells. The properties of CLL B-cell receptors (BCR) resemble those observed in normal B cells upon Ag interaction, and gene profiling analyses revealed that both subsets share striking similarities with the so-called memory B cells. The detailed analyses of the complementary determining region 3 (CDR3) sequences of the leukemic immunoglobulin (Ig) receptors showed that unrelated patients in different parts of the world express very similar if not identical BCR. Remarkably, similar VHDJH rearrangements have been identified in both UM- and M-CLL, suggesting an antigenic selection in both subsets of the disease. From all this evidence, the concept has arisen that the cell of origin, regardless its mutational status, has to be {"}an Ag-experienced{"} B cell that gives rise to a malignant clone that appears to be more dynamic than previously appreciated and whose progression is favored by a number of molecular and cellular interactions that occur in tissues.",
author = "Paolo Ghia and Federico Caligaris-Cappio",
year = "2006",
month = "4",
doi = "10.1053/j.seminoncol.2006.01.009",
language = "English",
volume = "33",
pages = "150--156",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The Origin of B-Cell Chronic Lymphocytic Leukemia

AU - Ghia, Paolo

AU - Caligaris-Cappio, Federico

PY - 2006/4

Y1 - 2006/4

N2 - An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen during the natural history of the disease. Unmutated (UM) cases show a remarkable skewing in IGHV gene usage. In addition, all CLL cases, both mutated (M) and UM, show a common surface phenotype which is significantly activated and similar to the surface phenotype of antigen (Ag)-experienced B cells. The properties of CLL B-cell receptors (BCR) resemble those observed in normal B cells upon Ag interaction, and gene profiling analyses revealed that both subsets share striking similarities with the so-called memory B cells. The detailed analyses of the complementary determining region 3 (CDR3) sequences of the leukemic immunoglobulin (Ig) receptors showed that unrelated patients in different parts of the world express very similar if not identical BCR. Remarkably, similar VHDJH rearrangements have been identified in both UM- and M-CLL, suggesting an antigenic selection in both subsets of the disease. From all this evidence, the concept has arisen that the cell of origin, regardless its mutational status, has to be "an Ag-experienced" B cell that gives rise to a malignant clone that appears to be more dynamic than previously appreciated and whose progression is favored by a number of molecular and cellular interactions that occur in tissues.

AB - An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen during the natural history of the disease. Unmutated (UM) cases show a remarkable skewing in IGHV gene usage. In addition, all CLL cases, both mutated (M) and UM, show a common surface phenotype which is significantly activated and similar to the surface phenotype of antigen (Ag)-experienced B cells. The properties of CLL B-cell receptors (BCR) resemble those observed in normal B cells upon Ag interaction, and gene profiling analyses revealed that both subsets share striking similarities with the so-called memory B cells. The detailed analyses of the complementary determining region 3 (CDR3) sequences of the leukemic immunoglobulin (Ig) receptors showed that unrelated patients in different parts of the world express very similar if not identical BCR. Remarkably, similar VHDJH rearrangements have been identified in both UM- and M-CLL, suggesting an antigenic selection in both subsets of the disease. From all this evidence, the concept has arisen that the cell of origin, regardless its mutational status, has to be "an Ag-experienced" B cell that gives rise to a malignant clone that appears to be more dynamic than previously appreciated and whose progression is favored by a number of molecular and cellular interactions that occur in tissues.

UR - http://www.scopus.com/inward/record.url?scp=33645971977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645971977&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.01.009

DO - 10.1053/j.seminoncol.2006.01.009

M3 - Article

C2 - 16616061

AN - SCOPUS:33645971977

VL - 33

SP - 150

EP - 156

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -